Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis
D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study
D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study
D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives
D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus
D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy
D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania
D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts
D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment
D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease
D3.265 - Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report
D3.268 - Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production
D3.269 - Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings
D3.270 - A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system
D3.272 - Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients
D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria
D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria
D3.275 - Anaphylaxis caused by polyhexanide
D3.276 - Acalabrutinib as premedication in platinum agents desensitization protocols: a case series supporting its role in enhancing tolerance with a repeatible efficacity
D3.277 - Features of severe anaphylaxis in children, data from the Moscow Pediatric Register
Download the app
The congress at your fingertips
Available on
Download